In this video, health care analyst David Williamson discusses Vertex Pharmaceuticals' recent third-quarter results, breaking down the company's surprising loss and estimate miss, along with the future of its lead drug, Incivek. Watch and find out what investors should take away from these disappointing results.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.